中国执业药师
中國執業藥師
중국집업약사
CHINA LICENSED PHARMACIST
2013年
11期
16-18,27
,共4页
吴胜红%姚铭%吴歌%时代红
吳勝紅%姚銘%吳歌%時代紅
오성홍%요명%오가%시대홍
抗骨质疏松药%临床应用%药物经济学参数
抗骨質疏鬆藥%臨床應用%藥物經濟學參數
항골질소송약%림상응용%약물경제학삼수
Anti-osteoporosis Agents%Clinical Application%Pharmacoeconomics Parameter
目的:通过对比分析我院抗骨质疏松(OP)药物在老年病门诊患者及全院的应用数据,为临床用药提供参考。方法:采用抗菌药物的用药频度(DDDs)、用药金额排序、限定日费用等药物经济学参数,对我院2010-2011年老年病门诊患者和全院抗OP药物处方进行回顾性分析。结果:与2010年比较,2011年抗OP药物总消费金额增长幅度(62.37%)远大于其他药品(7.90%),双膦酸盐类药物和钙制剂临床用药量较为平稳,但所占份额均有所下降,维生素D及活性代谢物和降钙素类药物应用量增幅较为突出;老年病门诊患者抗OP用药消耗金额与DDDs数据同步性较好,患者治疗费用更合理,而全院消耗金额与DDDs数据同步性较差;全院及老年病门诊双膦酸盐类药物和活性维生素D类的DDDs及销售金额均最高;阿法骨化醇DDDs明显大于骨化三醇,患者长期应用过程中更具有药物经济学比较优势,有助于提高患者用药依从性。结论:抗OP药物的药物经济学分析和用药趋势调查,应针对临床实际,在进行相关疾病治疗药物分析时采集专业科室的数据更能反映其临床应用的合理性。
目的:通過對比分析我院抗骨質疏鬆(OP)藥物在老年病門診患者及全院的應用數據,為臨床用藥提供參攷。方法:採用抗菌藥物的用藥頻度(DDDs)、用藥金額排序、限定日費用等藥物經濟學參數,對我院2010-2011年老年病門診患者和全院抗OP藥物處方進行迴顧性分析。結果:與2010年比較,2011年抗OP藥物總消費金額增長幅度(62.37%)遠大于其他藥品(7.90%),雙膦痠鹽類藥物和鈣製劑臨床用藥量較為平穩,但所佔份額均有所下降,維生素D及活性代謝物和降鈣素類藥物應用量增幅較為突齣;老年病門診患者抗OP用藥消耗金額與DDDs數據同步性較好,患者治療費用更閤理,而全院消耗金額與DDDs數據同步性較差;全院及老年病門診雙膦痠鹽類藥物和活性維生素D類的DDDs及銷售金額均最高;阿法骨化醇DDDs明顯大于骨化三醇,患者長期應用過程中更具有藥物經濟學比較優勢,有助于提高患者用藥依從性。結論:抗OP藥物的藥物經濟學分析和用藥趨勢調查,應針對臨床實際,在進行相關疾病治療藥物分析時採集專業科室的數據更能反映其臨床應用的閤理性。
목적:통과대비분석아원항골질소송(OP)약물재노년병문진환자급전원적응용수거,위림상용약제공삼고。방법:채용항균약물적용약빈도(DDDs)、용약금액배서、한정일비용등약물경제학삼수,대아원2010-2011년노년병문진환자화전원항OP약물처방진행회고성분석。결과:여2010년비교,2011년항OP약물총소비금액증장폭도(62.37%)원대우기타약품(7.90%),쌍련산염류약물화개제제림상용약량교위평은,단소점빈액균유소하강,유생소D급활성대사물화강개소류약물응용량증폭교위돌출;노년병문진환자항OP용약소모금액여DDDs수거동보성교호,환자치료비용경합리,이전원소모금액여DDDs수거동보성교차;전원급노년병문진쌍련산염류약물화활성유생소D류적DDDs급소수금액균최고;아법골화순DDDs명현대우골화삼순,환자장기응용과정중경구유약물경제학비교우세,유조우제고환자용약의종성。결론:항OP약물적약물경제학분석화용약추세조사,응침대림상실제,재진행상관질병치료약물분석시채집전업과실적수거경능반영기림상응용적합이성。
Objective:The comparison and analysis were conducted of the application data of anti-osteoporosis agents used in geriatric outpatients and other patients in our hospital so as to provide references for the clinical rational drug use. Methods:A retrospective analysis was carried out of the application of anti-osteoporosis agents in geriatric outpatients and in our hospital from 2010 to 2011 using the economic parameters such as DDDs, the ordering of drug consumption and daily defined cost. Results: Compared with 2010, the growth rate (62.37%) of the total amount of anti-osteoporosis drug consumptions was greater than that of other drugs (7.90%) in 2011. The clinical applications of bisphosphonates and calcium preparations were relatively stable, but the proportions declined. The growth rate of vitamin D and its active metabolite and calcitonin drugs in outpatients increased greatly. Good synchronous data of the consumption sum and DDDs in geriatric outpatients was obtained and the treatment cost was more reasonable. However the synchronous data of the consumption sum and DDDs in the patients of whole hospital was not satisfactory. The highest DDDs and sales amount of bisphosphonates and active vitamin D were showed which were used in geriatric outpatients and the whole hospital. The DDDs of alfacalcidol was obviously higher than that of calcitriol. Comparative advantage of pharmacoeconomics was proved in patient’s long-term application of the drugs, which was helpful to improve the compliance with medication in patients. Conclusion:The pharmacoeconomic analysis of anti-osteoporosis agents and the investigation of drug use tendency should be aimed at clinical situation. It can be more reflective of clinical rationality of medication to collect the data from professional departments during the analysis of drugs for related disease therapy.